- Home
- JBDI vs LGVN Comparison
JBDI vs LGVN Comparison
Compare JBDI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | LGVN |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | Singapore | United States |
| Employees | 104 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 11.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JBDI | LGVN |
|---|---|---|
| Price | $0.61 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 30.8K | ★ 9.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.52 | $0.48 |
| 52 Week High | $2.28 | $1.83 |
Technical Indicators
Market Signals| Indicator | JBDI | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 62.58 |
| Support Level | $0.52 | $0.55 |
| Resistance Level | $1.09 | $1.22 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 46.18 | 72.97 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.